These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 15501070

  • 21. Evaluation of transition-state mimics in a superior BACE1 cleavage sequence as peptide-mimetic BACE1 inhibitors.
    Hattori Y, Kobayashi K, Deguchi A, Nohara Y, Akiyama T, Teruya K, Sanjoh A, Nakagawa A, Yamashita E, Akaji K.
    Bioorg Med Chem; 2015 Sep 01; 23(17):5626-40. PubMed ID: 26264846
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Synthesis of potent beta-secretase inhibitors containing a hydroxyethylamine dipeptide isostere and their structure-activity relationship studies.
    Tamamura H, Kato T, Otaka A, Fujii N.
    Org Biomol Chem; 2003 Jul 21; 1(14):2468-73. PubMed ID: 12956063
    [Abstract] [Full Text] [Related]

  • 25. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease.
    Kádas J, Weber IT, Bagossi P, Miklóssy G, Boross P, Oroszlan S, Tözsér J.
    J Biol Chem; 2004 Jun 25; 279(26):27148-57. PubMed ID: 15102858
    [Abstract] [Full Text] [Related]

  • 26. Understanding HTLV-I protease.
    Shuker SB, Mariani VL, Herger BE, Dennison KJ.
    Chem Biol; 2003 May 25; 10(5):373-80. PubMed ID: 12770819
    [No Abstract] [Full Text] [Related]

  • 27. Effect of prime-site sequence of retro-inverso-modified HTLV-1 protease inhibitor.
    Awahara C, Tatsumi T, Furuta S, Shinjoh G, Konno H, Nosaka K, Kobayashi K, Hattori Y, Akaji K.
    Bioorg Med Chem; 2014 Apr 15; 22(8):2482-8. PubMed ID: 24680060
    [Abstract] [Full Text] [Related]

  • 28. KMI-008, a novel beta-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides.
    Shuto D, Kasai S, Kimura T, Liu P, Hidaka K, Hamada T, Shibakawa S, Hayashi Y, Hattori C, Szabo B, Ishiura S, Kiso Y.
    Bioorg Med Chem Lett; 2003 Dec 15; 13(24):4273-6. PubMed ID: 14643307
    [Abstract] [Full Text] [Related]

  • 29. Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme.
    Zhang M, Nguyen JT, Kumada HO, Kimura T, Cheng M, Hayashi Y, Kiso Y.
    Bioorg Med Chem; 2008 Jul 15; 16(14):6880-90. PubMed ID: 18558491
    [Abstract] [Full Text] [Related]

  • 30. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors.
    Iserloh U, Wu Y, Cumming JN, Pan J, Wang LY, Stamford AW, Kennedy ME, Kuvelkar R, Chen X, Parker EM, Strickland C, Voigt J.
    Bioorg Med Chem Lett; 2008 Jan 01; 18(1):414-7. PubMed ID: 18023580
    [Abstract] [Full Text] [Related]

  • 31. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors.
    Nguyen JT, Zhang M, Kumada HO, Itami A, Nishiyama K, Kimura T, Cheng M, Hayashi Y, Kiso Y.
    Bioorg Med Chem Lett; 2008 Jan 01; 18(1):366-70. PubMed ID: 18006315
    [Abstract] [Full Text] [Related]

  • 32. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere.
    Kiso Y.
    Biopolymers; 1996 Jan 01; 40(2):235-44. PubMed ID: 8785365
    [Abstract] [Full Text] [Related]

  • 33. Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II.
    Muthas D, Nöteberg D, Sabnis YA, Hamelink E, Vrang L, Samuelsson B, Karlén A, Hallberg A.
    Bioorg Med Chem; 2005 Sep 15; 13(18):5371-90. PubMed ID: 16054370
    [Abstract] [Full Text] [Related]

  • 34. Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo.
    Machauer R, Laumen K, Veenstra S, Rondeau JM, Tintelnot-Blomley M, Betschart C, Jaton AL, Desrayaud S, Staufenbiel M, Rabe S, Paganetti P, Neumann U.
    Bioorg Med Chem Lett; 2009 Mar 01; 19(5):1366-70. PubMed ID: 19195887
    [Abstract] [Full Text] [Related]

  • 35. Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution.
    Miura T, Hidaka K, Uemura T, Kashimoto K, Hori Y, Kawasaki Y, Ruben AJ, Freire E, Kimura T, Kiso Y.
    Bioorg Med Chem Lett; 2010 Aug 15; 20(16):4836-9. PubMed ID: 20634066
    [Abstract] [Full Text] [Related]

  • 36. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.
    Tözsér J, Zahuczky G, Bagossi P, Louis JM, Copeland TD, Oroszlan S, Harrison RW, Weber IT.
    Eur J Biochem; 2000 Oct 15; 267(20):6287-95. PubMed ID: 11012683
    [Abstract] [Full Text] [Related]

  • 37. Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design.
    Li M, Laco GS, Jaskolski M, Rozycki J, Alexandratos J, Wlodawer A, Gustchina A.
    Proc Natl Acad Sci U S A; 2005 Dec 20; 102(51):18332-7. PubMed ID: 16352712
    [Abstract] [Full Text] [Related]

  • 38. Inhibitors of aspartic proteases in human diseases: molecular modeling comes of age.
    Hoegl L, Korting HC, Klebe G.
    Pharmazie; 1999 May 20; 54(5):319-29. PubMed ID: 10368824
    [Abstract] [Full Text] [Related]

  • 39. Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1.
    Yang W, Lu W, Lu Y, Zhong M, Sun J, Thomas AE, Wilkinson JM, Fucini RV, Lam M, Randal M, Shi XP, Jacobs JW, McDowell RS, Gordon EM, Ballinger MD.
    J Med Chem; 2006 Feb 09; 49(3):839-42. PubMed ID: 16451048
    [Abstract] [Full Text] [Related]

  • 40. Design and synthesis of BACE1 inhibitors containing a novel norstatine derivative (2R,3R)-3-amino-2-hydroxy-4-(phenylthio)butyric acid.
    Ziora Z, Kasai S, Hidaka K, Nagamine A, Kimura T, Hayashi Y, Kiso Y.
    Bioorg Med Chem Lett; 2007 Mar 15; 17(6):1629-33. PubMed ID: 17251016
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.